171 related articles for article (PubMed ID: 25144624)
1. Methylated Glutathione S-transferase 1 (mGSTP1) is a potential plasma free DNA epigenetic marker of prognosis and response to chemotherapy in castrate-resistant prostate cancer.
Mahon KL; Qu W; Devaney J; Paul C; Castillo L; Wykes RJ; Chatfield MD; Boyer MJ; Stockler MR; Marx G; Gurney H; Mallesara G; Molloy PL; Horvath LG; Clark SJ;
Br J Cancer; 2014 Oct; 111(9):1802-9. PubMed ID: 25144624
[TBL] [Abstract][Full Text] [Related]
2. Serum Free Methylated Glutathione S-transferase 1 DNA Levels, Survival, and Response to Docetaxel in Metastatic, Castration-resistant Prostate Cancer: Post Hoc Analyses of Data from a Phase 3 Trial.
Mahon KL; Qu W; Lin HM; Spielman C; Cain D; Jacobs C; Stockler MR; Higano CS; de Bono JS; Chi KN; Clark SJ; Horvath LG
Eur Urol; 2019 Sep; 76(3):306-312. PubMed ID: 30466891
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic markers in circulating cell-free DNA as prognostic markers for survival of castration-resistant prostate cancer patients.
Hendriks RJ; Dijkstra S; Smit FP; Vandersmissen J; Van de Voorde H; Mulders PFA; van Oort IM; Van Criekinge W; Schalken JA
Prostate; 2018 Apr; 78(5):336-342. PubMed ID: 29330943
[TBL] [Abstract][Full Text] [Related]
4. Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer.
Nagaya N; Nagata M; Lu Y; Kanayama M; Hou Q; Hotta ZU; China T; Kitamura K; Matsushita K; Isotani S; Muto S; Sakamoto Y; Horie S
PLoS One; 2020; 15(1):e0226219. PubMed ID: 31986176
[TBL] [Abstract][Full Text] [Related]
5. Phase 2 study of circulating microRNA biomarkers in castration-resistant prostate cancer.
Lin HM; Mahon KL; Spielman C; Gurney H; Mallesara G; Stockler MR; Bastick P; Briscoe K; Marx G; Swarbrick A; Horvath LG
Br J Cancer; 2017 Apr; 116(8):1002-1011. PubMed ID: 28278515
[TBL] [Abstract][Full Text] [Related]
6. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy.
Bastian PJ; Palapattu GS; Lin X; Yegnasubramanian S; Mangold LA; Trock B; Eisenberger MA; Partin AW; Nelson WG
Clin Cancer Res; 2005 Jun; 11(11):4037-43. PubMed ID: 15930338
[TBL] [Abstract][Full Text] [Related]
7. Measurement of circulating cell-free DNA in relation to 18F-fluorocholine PET/CT imaging in chemotherapy-treated advanced prostate cancer.
Kwee S; Song MA; Cheng I; Loo L; Tiirikainen M
Clin Transl Sci; 2012 Feb; 5(1):65-70. PubMed ID: 22376260
[TBL] [Abstract][Full Text] [Related]
8. GSTP1 CpG island hypermethylation for DNA-based detection of occult tumor cells in surgical margins after radical prostatectomy.
Jentzmik F; Krause H; Reichelt U; Schrader AJ; Schrader M; Baumunk D; Cash H; Miller K; Schostak M
World J Urol; 2012 Aug; 30(4):541-6. PubMed ID: 21947551
[TBL] [Abstract][Full Text] [Related]
9. Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer.
Okegawa T; Nutahara K; Higashihara E
Int J Urol; 2010 May; 17(5):466-75. PubMed ID: 20337729
[TBL] [Abstract][Full Text] [Related]
10. Hypermethylation of the CpG islands in the promoter region flanking GSTP1 gene is a potential plasma DNA biomarker for detecting prostate carcinoma.
Chuang CK; Chu DC; Tzou RD; Liou SI; Chia JH; Sun CF
Cancer Detect Prev; 2007; 31(1):59-63. PubMed ID: 17291695
[TBL] [Abstract][Full Text] [Related]
11. Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis.
Wu T; Giovannucci E; Welge J; Mallick P; Tang WY; Ho SM
Br J Cancer; 2011 Jun; 105(1):65-73. PubMed ID: 21654682
[TBL] [Abstract][Full Text] [Related]
12. Promoter hypermethylation in circulating blood cells identifies prostate cancer progression.
Rouprêt M; Hupertan V; Catto JW; Yates DR; Rehman I; Proctor LM; Phillips J; Meuth M; Cussenot O; Hamdy FC
Int J Cancer; 2008 Feb; 122(4):952-6. PubMed ID: 17960617
[TBL] [Abstract][Full Text] [Related]
13. Prostate cancer molecular detection in plasma samples by glutathione S-transferase P1 (GSTP1) methylation analysis.
Dumache R; Puiu M; Motoc M; Vernic C; Dumitrascu V
Clin Lab; 2014; 60(5):847-52. PubMed ID: 24839830
[TBL] [Abstract][Full Text] [Related]
14. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
[TBL] [Abstract][Full Text] [Related]
15. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer.
Ellinger J; Haan K; Heukamp LC; Kahl P; Büttner R; Müller SC; von Ruecker A; Bastian PJ
Prostate; 2008 Jan; 68(1):42-9. PubMed ID: 18004747
[TBL] [Abstract][Full Text] [Related]
16. GSTP1 promoter methylation is associated with recurrence in early stage prostate cancer.
Maldonado L; Brait M; Loyo M; Sullenberger L; Wang K; Peskoe SB; Rosenbaum E; Howard R; Toubaji A; Albadine R; Netto GJ; Hoque MO; Platz EA; Sidransky D
J Urol; 2014 Nov; 192(5):1542-8. PubMed ID: 24769028
[TBL] [Abstract][Full Text] [Related]
17. Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.
Chung JS; Wang Y; Henderson J; Singhal U; Qiao Y; Zaslavsky AB; Hovelson DH; Spratt DE; Reichert Z; Palapattu GS; Taichman RS; Tomlins SA; Morgan TM
Neoplasia; 2019 Aug; 21(8):802-809. PubMed ID: 31276932
[TBL] [Abstract][Full Text] [Related]
18. Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study.
He L; Gao L; Shi Z; Li Y; Zhu L; Li S; Zhang P; Zheng G; Ren Q; Li Y; Hu B; Feng F
PLoS One; 2015; 10(3):e0119481. PubMed ID: 25798582
[TBL] [Abstract][Full Text] [Related]
19. Association between lifestyle factors and CpG island methylation in a cancer-free population.
Brait M; Ford JG; Papaiahgari S; Garza MA; Lee JI; Loyo M; Maldonado L; Begum S; McCaffrey L; Howerton M; Sidransky D; Emerson MR; Ahmed S; Williams CD; Hoque MO
Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):2984-91. PubMed ID: 19861513
[TBL] [Abstract][Full Text] [Related]
20. Impact of the location of CpG methylation within the GSTP1 gene on its specificity as a DNA marker for hepatocellular carcinoma.
Jain S; Chen S; Chang KC; Lin YJ; Hu CT; Boldbaatar B; Hamilton JP; Lin SY; Chang TT; Chen SH; Song W; Meltzer SJ; Block TM; Su YH
PLoS One; 2012; 7(4):e35789. PubMed ID: 22536438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
